LCI earnings

Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a

Q1 Business and Financial Highlights: Net Sales were $75.1 MillionGross Margin 17%, Adjusted Gross Margin 18%Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding QuarterCash Was $78 Million at September 30Sold Several Discontinued ANDAs for Approximately $3 MillionPipeline Updates: Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023;Generic FLOVENT® DISKUS® ANDA Filing Anticipated Spring of Next Year, Earlier Granted CGT Status by FDA TREVOSE, Pa., Nov. 2, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its f

TREVOSE, Pa., Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 855-327-6837 from the U.S. or Canada, or 631-891-4304 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners ar

Q4 Business and Financial Highlights: Net Sales were $74.2 MillionAdjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30Completed Major Elements of November 2021 Restructuring PlanPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Over 90% Complete, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023Expect to File IND for Biosimilar Insulin Aspart by First Half of 2023Generic FLOVENT® DISKUS® Product On Track for ANDA Filing Early Next Calendar Year, Granted CGT Status by FDA Expect Partner to Commence Pilot PK Trials for Generic Spiriva® Handihaler® by Year End 2022Licensed a Filed ANDA for Mesalamine Del

TREVOSE, Pa., Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August 24, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com

Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of November 2021 Restructuring Plan Expected to be Completed by June 30Pivotal Biosimilar Insulin Glargine Clinical Trial ProgressingTREVOSE, Pa., May 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its fiscal 2022 third quarter ended March 31, 2022.  "For the quarter, ongoing competitive pressures and unusually high product returns for a few key

TREVOSE, Pa., April 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions. The conference call will be available to interested parties by dialing 877-344-8082 from the U.S. or Canada, or 213-992-4618 from international locations. The call will be broadcast via the Internet at www.Lannett.

TREVOSE, Pa., Feb. 3, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021.  "For the quarter, ongoing and increasing competitive pricing pressure across our product offering negatively impacted net sales and gross margin," said Tim Crew, chief executive officer of Lannett. "While we anticipate this pricing environment to persist over the near term, we continue to execute on our core strategies to build our product pipeline, advance our durable insulin and respiratory assets and reduce

TREVOSE, Pa., Jan. 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2022 second quarter on Thursday, February 3, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions. The conference call will be available to interested parties by dialing 888-771-4371 from the U.S. or Canada, or 847-585-4405 from international locations, passcode 50278391. The call will be broadcast via the I

PHILADELPHIA, Nov. 3, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its fiscal 2022 first quarter ended September 30, 2021.  "For the quarter, solid sales of several key products contributed to our better than expected topline," said Tim Crew, chief executive officer of Lannett. "Our gross margin however, was lower than anticipated, largely due to increasing competitive pressure on our base portfolio and product mix. Our strong cash position at September 30, 2021 grew to more than $105 million from approximately $93 million at June

PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2022 first quarter on Wednesday, November 3, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions. The conference call will be available to interested parties by dialing 888-771-4371 from the U.S. or Canada, or 847-585-4405 from international locations, passcode 50246855. The call will be broadcast via the I

PHILADELPHIA, Aug. 25, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its fiscal 2021 fourth quarter and full year ended June 30, 2021.  "With the recently signed agreement to be the exclusive U.S. distributor of a generic Spiriva® Handihaler®, we now have disclosed at least five large, durable assets in our pipeline," said Tim Crew, chief executive officer of Lannett. "Each of these products has the potential to both be a significant contributor to our financial performance and to do so for an extended period of time. Combined, the

PHILADELPHIA, Aug. 18, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2021 fourth quarter and full year on Wednesday, August 25, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions. The conference call will be available to interested parties by dialing 888-771-4371 from the U.S. or Canada, or 847-585-4405 from international locations, passcode 50215666. The call will be broad